Therapeutic Design
Our generative model designs biologics with optimized properties such as stability and potency in the case of RNA. We have validated the ability to make best-in-class therapies in mice using this model.
Generative models design biologics optimized for therapeutic efficacy from the start.
Candidates are engineered for high manufacturing yields and developability, limiting manufacturing delays.
In-silico assessment of thermal stability, viscosity, chemical liabilities, and purification compatibility.
Leads delivered production-ready: potent, stable, non-immunogenic, and built for scalable manufacturing.
Generate antibody sequences conditioned on 3D epitope structure using equivariant diffusion models trained on proprietary data.
Predict therapeutic and manufacturing properties across RNA, peptides, DNA, and antibody biologics.
Predict aggregation propensity, clearance, and expression yield to de-risk candidates before entering CMC.
Visualize sequence landscapes, Pareto fronts, and campaign progress. Export reports for regulatory and partner discussions.
AbInitio's Therascript platform was incorporated into the Fingerprint consortium, a multi-institutional initiative leveraging agentic AI for Alzheimer's drug discovery. The team has advanced to the finals of the Alzheimer's Disease Data Initiative AI Prize.
AbInitio was selected for MIT's R2E program, which provides funding, mentorship, and resources to translate breakthrough biomedical research into scalable ventures.
AbInitio was chosen for the 5050 program by Fifty Years, a venture fund that backs founders building companies to solve the world's biggest problems through science and technology.
Join the pharma and biotech teams using Therascript to go from target to lead in weeks, not years.
Get in Touch
Our generative model designs biologics with optimized properties such as stability and potency in the case of RNA. We have validated the ability to make best-in-class therapies in mice using this model.